In QuotedData’s morning briefing 2 October 2024:

• RTW Biotech Opportunities (RTW) announced a new investment in Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumours. RTW, alongside other investment vehicles managed by RTW Investments (the investment manager), co-led Aktis’s Series B round, raising $175m in an oversubscribed and upsized financing to further advance its proprietary radiopharmaceutical pipelie. The funding will be used to further advance the company’s differentiated radiopharmaceuticals pipeline, including its first-in-class Nectin-4-targeted miniprotein radioconjugate.